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The concept of myocardial remodeling links an initial pathological insult to a progressive geometric change of the ventricle. Currently, our
concepts of the remodeling process have evolved to include not only changes in ventricular size and shape, but cellular and molecular
remodeling, particularly as the ventricle evolves towards failure. In recent years, much attention has focused on the role of cell–extracellular
matrix (ECM) connections in this process. In this review, we will specifically delineate how cell membrane-linked molecules of three classes:
integrins, membrane-type matrix metalloproteinases, and ADAMs (A Disintegrin And Metalloproteinase) might play crucial roles in
myocardial remodeling. These molecules are essential for cell–ECM adhesion, cell signaling, matrix modification, and proteolysis of surface
receptors. Our goal is to put forth concepts on how they might interrelate to modulate the remodeling process in the heart.
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The concept of myocardial remodeling links an initial
pathological insult to a progressive geometric change of the
ventricle. This process may only necessitate a single direct
attack on the ventricle and does not necessarily require
continued insults. Discussion about remodeling inevitably
prompts talk of hypertrophy, dilation and heart failure.
Currently, our concepts of the remodeling process have
evolved to include not only geometric remodeling, but
cellular and molecular remodeling, particularly as the
ventricle evolves towards failure [1–3]. Despite dedicated
efforts, we still have an incomplete understanding of it. In
recent years, much attention has focused on the role of cell-0008-6363/$ - see front matter. European Society of Cardiology. Published by El
doi:10.1016/j.cardiores.2005.09.004
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1 These authors contributed equally to this manuscript.extracellular matrix connections in remodeling. How these
connections are maintained and change with remodeling is
the subject of many chapters within the current volume. In
this review, we will specifically delineate how cell
membrane-linked molecules of three classes: integrins,
membrane-type matrix metalloproteinases (MT-MMPs)
and ADAMs (A Disintegrin And Metalloproteinase) might
play crucial roles in this process. These molecules can
influence cell–ECM adhesion, cell signaling, matrix mod-
ification and even proteolysis of surface receptors. Our goal
is to put forth concepts on how they might interrelate to
modulate the remodeling process in the heart.2. Integrins
Integrins are glycoprotein transmembrane receptors
which link extracellular matrix (ECM) and the cellular
cytoskeleton. They are non-covalently bound heterodimers
composed of a and h subunits with a large extracellular69 (2006) 574 – 584sevier B.V.
Fig. 1. Domain structure of integrins, MT-MMPs and ADAMS. Abbreviations: MIDAS, metal ion-dependent adhesion site; Cys-rich, cysteine-rich domain;
Sig, signal peptide; Pro, propeptide; Fu, furin recognition motif; Catalytic, catalytic domain; Zn, zinc; Hemopexin, hemopexin/vitronectin like domain; TM,
transmembrane domain; Cy, cytosolic tail; GPI, glycosylphosphatidyl-inositol; H, proline-rich hinge region; EGF, epidermal growth factor-like domain; TS,
thrombospondin motifs.
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 domain, a single transmembrane span and short cytoplasmic
tails (Fig. 1). These molecules orchestrate both cell adhesion
and bi-directional intracellular signaling [4]. As multi-func-
tional molecules, integrins are involved in organogenesis,
regulation of gene expression, cell proliferation, differ-
entiation, migration and death. Importantly, they function
as mechanotransducers, converting mechanical forces to
biochemical signals.
Integrins are expressed in most cell types. What makes
this class of receptors complex is that one cell can express a
variety of integrins and that the expression pattern can
change during development or with disease. In the cardio-
vascular system, integrins are expressed in cardiac myocytes
and fibroblasts as well as cells composing the vasculature,
blood and neurons. Studies have shown that integrins are
involved in heart formation, function and disease. Given
space limitations of the current review, the reader is referred
to more comprehensive ones by our own group and others on
integrin structure, expression and signaling [5–7].3. Integrin function and the myocardium
In studies which mechanically stretched cardiac fibro-
blasts, activation of two hypertrophic-related kinases,
extracellular signal-regulated kinase (ERK2) and c-Jun-terminal kinase (JNK1) was demonstrated to occur through
cell surface integrins [8]. Integrins were linked to these
signaling events by a combination of experiments in which
cells were either bound to matrix ligands of integrins
(laminin, fibronectin and vitronectin) or where integrin
function was inhibited by specific anti-integrin antibodies.
Integrins also mediate activation of transforming growth
factor h (TGF-h) [9], an important cytokine in the fibrotic
response of the heart. TGF-h stimulation of fibroblasts
caused increased expression of a5h1 integrins [10], con-
versely, overexpression of this integrin heterodimer
increased TGF-h expression [11]. Taken together, it is
apparent that integrins participate in events of hypertrophic
and post-infarct remodeling.
Changes in ECM amount and distribution occur follow-
ing pathophysiological or growth factor mediated events
such as pressure overload, myocardial infarction or follow-
ing production of substances such as endothelin-1 or
angiotensin II (AII). Terracio et al. were some of the first
investigators to document the importance of integrins in the
myocardium and how their expression was changed with
hypertrophy [12]. They showed that with hypertrophy, a1
integrin (a collagen binding subunit when paired with h1)
increased in parallel with collagen content of the heart itself.
Gullberg et al. noted that integrin and PDGF-mediated
signaling intersected, in that PDGF-stimulated collagen gel
A.M. Manso et al. / Cardiovascular Research 69 (2006) 574–584576
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 contraction caused by cardiac fibroblasts, could be partly
inhibited by h1 integrin antibodies [13]. Sadoshima and
Izumo subsequently performed studies which utilized
mechanical loading of cultured myocytes to simulate
hemodynamic loading of the intact myocardium. They and
other investigators showed how the mechanical stimulus
induced a variety of intracellular signaling pathways such as
phospholipases C, D, and A2, protein kinase C, tyrosine
kinases, p21 MAP kinases, and 90 kD S6 kinase [14,15].
Many of these pathways are known to be involved in growth
factor and integrin signaling cascades. These same authors
also showed that stretch of myocytes provoked paracrine
release of factors such as AII which also provoke hyper-
trophy [16]. AII stimulation of cardiac fibroblasts has been
shown to increase expression of a8h1 and also intensify
immunomicroscopic expression of h1integrin [17,18].
Several groups, including our own, have shown that the
hypertrophic response of cultured myocytes and the intact
ventricle can cause increased expression of integrins such as
a7 and h1; and that integrins (e.g. overexpression of h1D
integrin) and ECM ligands for integrin receptors (such as
fibronectin) can invoke the hypertrophic response pathway
independent of growth factors [19–21]. It has also become
clear that there is synergy between growth factor and integrin
mediated stimulation of hypertrophy. Much of this overlap
may function through focal adhesion kinase (FAK), FAK
related kinases (such as Pyk2) and ultimately signal through
protein kinase C (PKC) and ERK related pathways [22–29].
Integrins have been shown to utilize FAK, src-Family
Kinases (Src), growth factor receptor-bound protein-2
(Grb2) and Ras to induce hypertrophic signals propagated
through p38 MAPK [30]. Agents known to induce cardiac
myocyte hypertrophy including endothelin-1 (ET-1) and
phenylephrine (PE) signal through pathways concomitantly
and perhaps synergistically with integrins. As discussed
more completely in other sources, integrins have also been
shown to interact with a host of other cell surface receptors in
the myocardium, including ones which may participate in the
remodeling process such as adrenergic, cholinergic and
calcium receptors [5,7,31–33]. Thus integrins can function
at multiple levels in the remodeling process.e 17, 20144. Membrane-type matrix metalloproteinases
MMPs are members of a family of zinc endopeptidases
that contribute to the degradation of ECM in processes such
as tumor expansion, angiogenesis and cardiac remodeling
[34–37]. MMPs are capable of digesting ECM and base-
ment membrane proteins, but these are not their only targets
as they are also able to cleave other MMPs, an array of other
proteases and protease inhibitors, growth factors, growth
factor binding proteins, chemokines, cytokines, cell surface
receptors and cell adhesion molecules [34,38]. Thereby,
MMPs control cell migration, proliferation, and apoptosis
[34].To date 25 different vertebrate MMPs have been
identified, of which 22 are found in humans [39]. Although
initially classified according to their substrate specificity, the
MMP classification is now based on their structure [40]. The
MMPs can be segregated into two groups: the soluble type,
which are released into the pericellular space, and those
anchored to the plasma membrane, the membrane type
MMPs (MT-MMPs), a focus of this review. Six distinct
members of the MT-MMP subfamily of MMPs have been
identified in human tissue [41,42]: MT1-, MT2-, MT3-,
MT4-, MT5-, and MT6-. A strict nomenclature of these MT-
MMPs has classified them as MMP14, 15, 16, 17, 24 and
25, respectively.5. MT-MMP structure and classification
The basic domain structure of MMPs includes (1) a
signal peptide that directs them to the endoplasmic
reticulum, (2) a propeptide with a zinc-interacting thiol
(SH) group that maintains the molecule in a latent form (i.e.
a zymogen), and (3) a catalytic domain containing the
highly conserved Zn2+ binding site [43]. With the exception
of MMP23 and the matrilysins (MMP7 and MMP26), all
other MMPs display a hemopexin/vitronectin-like domain
that influences substrate specificity and the binding of the
MMPs to their inhibitors, ‘‘tissue inhibitors of MMPs’’ or
TIMPs, and a proline-rich hinge region that links the
catalytic domain to the hemopexin domain [44] (for more
information on MMP structure see Ref. [39]).
The MT-MMPs contain all protein domains characteristic
of the more generalized MMP class mentioned above (Fig.
1). The key difference between MT-MMP and the other
MMPs is the membrane-anchoring domain of MT-MMPs
which allows for a unique cellular localization and also
provides for orchestrating a new set of substrate targets,
distinct interactions with the TIMPs, and produces a non-
conventional regulatory mechanism of these proteases
involving enzyme internalization, processing, and ectodo-
main shedding [45].
On the basis of their method of attachment to the plasma
membrane, MT-MMPs may be classified into two groups:
transmembrane-type and glycosylphosphatidyl-inositol
(GPI)-type. MT1-, MT2-, MT3- and MT5-MMP are type I
transmembrane proteins with a short cytoplasmic tail that is
involved in the regulation of intracellular trafficking and
activity of these proteases [46–48]. MT4- and MT6-MMP
are distinguished in that they are not transmembrane
proteins but are bound to the cell surface by a GPI-mediated
mechanism [49,50].
All MMPs are produced as zymogens containing a
secretory signal sequence and a propeptide whose proteo-
lytic cleavage is required for their activation. Most of the
MMPs are activated outside the cell by other MMPs or
serine proteinases. An important difference between MT-
MMPs and most soluble MMPs is that they are mainly
A.M. Manso et al. / Cardiovascular Research 69 (2006) 574–584 577activated intracellularly. A furin recognition motif localized
between the propeptide and the catalytic domain in all six
MT-MMPs is cleaved by pro-protein convertases in the
trans-Golgi network. In this manner it insures that MT-
MMPs are active when they reach the cell membrane
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 6. MT-MMP regulation and function
As with the other MMP, MT-MMP function or activity is
regulated in several ways: transcriptional, via proenzyme
activation and by inhibition [34]. Additionally, MT-MMP
activity can be regulated by shedding and endocytosis [45],
by factors such as cytokines like interleukin [51], TNF-a
[52] or TGF-h [53]; by mechanical stretch [54] and by
interactions with ECM proteins like collagen, fibronectin or
fibrinogen [38,55,56] which are in turn bound by integrins.
The MT-MMPs can degrade several ECM components as
well as other membrane or matrix-bound/pericellular pro-
teins. The spectrum of ECM proteins that can be degraded is
broad and includes fibronectin, tenascin, nidogen, aggrecan,
perlecan, laminin and native type-I and type-III collagens.
Non-ECM proteins cleaved by MT-MMPs include cell
adhesion molecules such as CD44 and pro-av integrin, as
well as cytokines like pro-TNF-a [44,57,58].
As noted previously, MMPs are synthesized as latent
enzymes that need to be activated. MT-MMPs, like some of
the soluble MMPs, serve an important role as activators of
other pro-MMPs [59]. One example was shown by Zhou et al.
[60] who studied MT1-MMP-deficient mice. They showed
that MT1-MMP was an in vivo activator of MMP-2
(gelatinase A). This process was regulated by TIMP-2
concentration. MT2-, MT5- and MT6-MMPs can also lead
to MMP2 activation [61,62]. This activity is facilitated by
avh3 integrin. It has been proposed that cross-talk between
MT1-MMP and avh3 integrin clustered in discrete regions
on the cell surface enhances pro-MMP2 activation [63]. This
begins to illustrate the complex interactions of membrane-
associated molecules which could modulate the remodeling
process in heart. MT1-MMP can also activate 1) MMP9 via
MMP2 orMMP3 [64] and 2) procollagenase-3 (MMP13), via
both MMP2 dependent and independent mechanisms.
Showing further interrelationships between the molecules
under discussion here, MT4-MMP has been shown to
enhance the activation of ADAMTS-4 [65]. Thus MT-MMPs
can provoke amplification of a pericellular proteolytic milieu.7. MT-MMPs in the heart
In the normal heart, MT1-, MT2- and MT3- transcripts
have been detected whereas no MT4-, MT5- or MT6-MMP
have been shown [41,42,66–69]. In the failing heart,
increased expression of MT1-MMP occurs [70]. The
mechanical and/or humoral stresses which occur duringpathological processes affect the activity and expression of
several MMPs in the heart. This includes activation of MT1-
MMP which is regulated in part by the angiotensin type 1
receptor (AT1R) [71,72].
In the heart, MT1-MMP has been the best characterized
MT-MMP to date. In vivo and in vitro experiments have
shown the upregulation of this MMP in heart and cardiac
cells under stress conditions such as pressure overload
[73], myocardial infarction [74], ischemia/reperfusion (I/R)
[72], humoral treatments [75] and mechanical stretch
[54,76]. Coker et al. [75] showed how MT1-MMP is
upregulated in porcine cardiac myocytes after neurohor-
monal stimulation with factors that have been linked to the
development of cardiac hypertrophy and heart failure, e.g.
ET-1, AII and Isoproterenol (Iso). In turn, the increased
activity of MT1-MMP evoked increased collagenase
activity and MMP2 content. This study is in contrast to
the one by Menon et al. where MT1-MMP transcript levels
did not change in adult rat cardiac myocytes stimulated
with Iso [77]. Strain and experimental protocol differences
could have lead to this variance. Furthermore, in a recent
study, MT1-MMP expression, activity and sub-cellular
localization were found to change during I/R [72]. In this
study Deschamps and colleagues showed how MT1-MMP
activity evaluated in cardiac tissue from pigs was increased
in ischemic areas after acute I/R. This was associated
with an increase in total MT1-MMP abundance and a
concomitant decrease in TIMP-4 as well as TIMP-3. The
increased MT1-MMP activity was associated with aug-
mented levels in the endosomal fraction after I/R,
suggesting that the increase could be due to changes in
trafficking of the enzyme. In the same study, microscopic
analysis of isolated porcine LV myocytes showed how
MT1-MMP can change its cellular localization during
hypoxia and re-oxygenation.
Mechanical stretch has been directly linked to activation
of MT1-MMP and MMP2 in several cell types including
cardiac myocytes [76,78]. Like the porcine studies above,
neonatal rat cardiac myocytes subjected to mechanical stress
increased transcript and protein expression of MT1-MMP
and MMP2 following stretch. These increases were com-
pletely blocked by Losartan, demonstrating that the effect is
mediated through the AT1 receptor. In agreement with this
result, Deschamps et al. showed that mechanically mediated
alterations in MMP activity in the intact heart are partially
regulated through the AT1R [71].
Several studies have also shown that MT1-MMP is
increased during the transition from compensated hyper-
trophy to heart failure [73,79]. EMMPRIN (extracellular
matrix metalloproteinase inducer) was also upregulated.
This likely facilitated an increase in MMP expression as
EMMPRIN has been shown to increase MMP2 activation in
non-cardiac cells [80,81]. EMMPRIN also forms a complex
with a3h1 integrin. This interaction may be another
membrane-associated nodal point for activation of MT1-
MMP and MMPs in heart [82].
A.M. Manso et al. / Cardiovascular Research 69 (2006) 574–584578
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main source of MMPs. In line with this, cardiac fibroblasts
are the main producers of MMPs and TIMPs in the
myocardium [73]. Polyakova et al. have shown that in
patients with heart failure due to aortic stenosis, increases in
ECM and activation of numerous MMPs as well as MT1-
MMP parallel proliferation of cardiac fibroblasts. More
directly, stretch of cardiac fibroblasts was shown to not only
regulate fibroblast mediated ECM deposition, proliferation
and differentiation [83,84] but also induce MT2-MMP
expression in cultured cardiac fibroblasts [54]. More
recently, collagen and TGF-h1 were shown to induce
MT1-MMP expression and enhance migration of cardiac
fibroblasts [85]. at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 17, 2014
http://cardiovascres.oxfordjournals.org/
m
 8. ADAMs: classification, structure and function
ADAMs (A Disintegrin And Metalloproteinase) belong
to a family of zinc transmembrane glycoproteins that have
essential functions in cell –cell interactions (such as
adhesion and fusion), in signaling, and in proteolysis (also
termed ectodomain shedding) of important cytokines,
cytokine receptors, and other targets [86]. A related family
of ADAMs is the secreted forms, ADAMTSs (TS=throm-
bospondin motifs) which also bind to the ECM [87]. Like
the MMPs, ADAMs also belong to the metzincin subgroup
of zinc proteases [88]. A key difference between ADAMs
and MMPs lies in the unique integrin receptor-binding
disintegrin domain present in ADAMs.
The structure of ADAMs consists of a prodomain, a
metalloprotease domain, a disintegrin domain, a cysteine-
rich domain, an EGF-like domain, a transmembrane domain
and a cytoplasmic tail (Fig. 1). The N-terminal prodomain
principally functions to keep the metalloprotease site
inactive but also acts as a chaperone for the proper folding
of ADAMs’ metalloprotease domain [86]. The metallopro-
tease domain hydrolyses protein substrates such as cyto-
kines and growth factors, as well as their respective
receptors. This process is termed ectodomain shedding
and ADAMs are often termed ‘‘Sheddases’’. The disintegrin
domain binds matrix ligands of integrin receptors such as
fibronectin. 11 ADAM disintegrin domains are known to
interact with integrin receptors at the specific location of the
‘‘disintegrin loop’’ found on many ADAM molecules [89].
Among the integrins that bind to the ADAM disintegrin
domain are a4h1, a4h7, a5h1, a6h1, a9h1, avh3, and
avh5 [90]. However, the most prominent integrin partner
for ADAMs is a9h1 [89]. The exact functions of the
cysteine-rich domain and the EGF-like domain are unclear.
The cytoplasmic tail of ADAMs is thought to be involved in
signaling and may also serve to assemble a group of
cytoplasmic adaptor molecules. Thus this multifunctional
molecule, like integrins, can participate in ‘‘inside-out
signaling’’ of metalloprotease activity; as well as ‘‘outside-
in’’ regulation of cell signaling.9. ADAM family members and expression
To date there have been 40 ADAMs identified in a
variety of species. Certain ADAMs are primarily expressed
in one tissue, whereas others show a broader expression
pattern in several somatic tissues. A total of 14 ADAMs are
expressed in a variety of somatic tissues and of those,
several (ADAMs 10, 11, 12, 15, 17, and 19) are expressed
in muscle [91]. Interestingly, in atrial tissue obtained from
patients with atrial fibrillation, it was found that mRNA and
protein levels of ADAM10 and ADAM15 were upregulated
compared to tissue from patients with no history of atrial
fibrillation [92]. This increased expression was thought to
be involved in the atrial remodeling that occurs with atrial
fibrillation. In addition, although ADAM11 expression was
thought to be dominantly in central nervous system tissue
where it is involved in adhesion of neurons and axon
guidance, it was also found transiently expressed in fetal and
perinatal cardiac tissue [93].10. ADAM function in the heart
Tumor necrosis factor-a converting enzyme or TACE
(ADAM17) has been shown to play an important role in
myocardial development as shown by studies from
ADAM17DZn /DZn null mutant mice [94–96]. These mice
have multiple abnormalities including a cardiac phenotype
characterized by both increased cardiomyocyte size (hyper-
trophy) and proliferation [94].
ADAM19 is highly expressed in the conotruncus and
endocardial cushion regions during cardiogenesis. This
ADAM also plays an essential role in cardiac development
as ADAM19 null mice display a ventricular septal defect,
abnormal aortic and pulmonic valve structures as well as
abnormal vasculature [97,98].
In addition to their role in cardiac organogenesis,
ADAMs are thought to be involved in cardiac hyper-
trophy as illustrated through studies of their shedding and
subsequent activation of heparin-binding epidermal
growth factor-like growth factor (HB-EGF) [99] (Fig.
2). ADAM12 has been linked to the hypertrophic
response of cultured neonatal rat cardiomyocytes stimu-
lated with G-protein coupled receptor (GPCR) agonists
such as PE, AII, and ET-1. Stimulation with GPCR
agonists leads to transactivation of EGFR [100] by HB-
EGF following the ectodomain shedding of HB-EGF
mediated by ADAM12. Expression of a dominant-
negative form of ADAM12 abolished the transactivation
of EGFR mediated by GPCR agonists. Use of the
protease inhibitor KB-R7785 attenuated hypertrophy
caused by pressure overload (using an aortic banding
model) as well as that caused by the in vivo stimulation
by the GPCR agonists PE and AII. These data suggested
that shedding of HB-EGF by ADAM12 is a component
of the signal transduction pathway leading to cardiac
Fig. 2. The role of ADAM 12 in the hypertrophic process. GPCR
stimulation by agonists such as phenylephrine (PE), AII or ET-1 leads to
ADAM-12 activation. The activated ADAM evokes ectodomain shedding
of the heparin-binding epidermal growth factor (HB-EGF), to allow EGF
stimulation of its cognate receptor. In turn this activates MAPK signaling
and cardiac hypertrophy.
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 hypertrophy. On the other hand, overexpression of
ADAM12 in skeletal muscle of dystrophin-deficient mdx
mice ameliorated the muscle cell necrosis and inflamma-
tion associated with this disease [101]. Although the
mechanisms by which this occurred was not entirely clear,
ADAM12 acting as an adhesion molecule may reduce
damage caused by loss of cell–ECM contact, a phenom-Fig. 3. A global diagram of how membrane associated proteases and integrins migh
can promote cardiac remodeling through several mechanisms: (1) by activating
cytokines or peptides, and (3) by interacting with integrins. ADAMs may be inv
including heparin-binding epidermal growth factor (HB-EGF), cytokines or pep
remodeling by causing ECM degradation. Integrins can participate in cardiac rem
cytokines such as TGF-h and (7) through shedding of their extracellular segmenenon that has been shown to lead to cell necrosis and
apoptosis. Alternatively, ADAM12 could benefit the mdx
muscle by shedding trophic factors such as HB-EGF
which may augment cell survival.
Expression of the soluble ADAMTS1 (ADAM with
thrombospondin motifs-1) was upregulated in the endo-
thelium as well as the myocardium of the infarcted rat
heart. This was particularly evident within 3 h following
the onset of the event, and especially in the infarcted zone
[102]. The change in expression of ADAMTS1 in this MI
model occurred more rapidly than changes in MMP
expression which have been also shown to be upregulated
after MI. The role that ADAMTS1 plays early after MI is
not precisely known. Its function is unlikely to be only
that of degradation of ECM components, since its
expression occurs so early in the MI time course. In
addition to their role in MI, ADAMs have also shown to
be involved in the process of ischemic preconditioning.
Ischemic preconditioning may activate ADAM17 via
GPCR signaling. In turn, ADAM17 may trigger additional
signal transduction processes by mediating TNFa shedding
[103].11. Interactions of integrins, MT-MMPs and ADAMS in
cardiac remodeling
The interactions of these three classes of membrane-
associated molecules in the cardiac remodeling process aret function in the context of the cardiac remodeling process. The MT-MMPs
soluble proMMPs, (2) by shedding or activating growth factors (GFs),
olved in remodeling (4) through shedding or activation of growth factors
tides, or (5) by interacting with GPCRs. ADAMs can also participate in
odeling by hypertrophic signaling in cardiac myocytes, by (6) activating
t.
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Fig. 4. Detailed examples of actual and hypothetical integrin, MT-MMP and
ADAM interactions in the myocardium. Panel A — A complex interplay
between cytokines, integrin, MT-MMPs and MMPs might modulate matrix
production, cell adhesion and cell proliferation. Here integrins bind the
inactive or latency-associated protein (LAP) form of TGF-h1 and cause its
activation and also increase expression of TGF-h. TGF-h in turn stimulates
expression of integrins and MT1-MMP. MT1-MMP then leads to activation
(directly/indirectly) of soluble MMPs and thus TNF-a activation. This
combination of events leads to modulation of matrix production, cell
adhesion and cell proliferation. Panel B — The matricellular protein OPN
is upregulated by AII stimulation of cardiac fibroblasts and also binds to
fibroblast integrins. Further, some of the integrins bound by OPN can bind
and activate MT1-MMP, and lead to activation of soluble MMPs like
MMP2 and MMP9. MT1-MMP may also process pro-forms of integrins.
Thus a complex interplay of integrins, integrin ligands and MMPs may
modulate dynamics of cell adhesion and release. Panel C — Shedding of
integrin ectodomains may occur during the transition from compensated
hypertrophy to heart failure. While the potential role of an ADAM in this
process is illustrated, this remains unproven in heart. Shedding of integrins
could rapidly ‘‘disconnect’’ cells from the ECM. The role of the shed
integrin fragment is currently unknown.
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 poorly understood. We will present some actual and
hypothetical conditions which might impact on myocardial
remodeling.
It is important to emphasize that many extracellular
proteases are expressed in a latent proenzyme state and that
their expression is inducible, perhaps responding to environ-
mental cues during cardiac remodeling [104]. It must also be
recognized that through the remodeling process, ECM can
alter its own bioactive properties via activation and release
of growth factors and other biologically active peptides
which are bound within the ECM. To date, little is known as
to the dynamic nature of the formation, maintenance, and
remodeling of the ECM though it is evident that modulation
of cell–matrix and cell–cell adhesion is an important
component of the dynamic remodeling process. Integrins,
MT-MMPs and ADAMS, as membrane associated mole-
cules, are likely to be important independent or collabo-
rative members of this molecular response pathway. A
global view of this is presented in Fig. 3.
One example (Fig. 4, panel A) is demonstrated by the
fact that avh6 integrins can bind and activate TGFh1
latency-associated protein (LAP) [9]. TGF-h is an important
cytokine in the fibrotic response of the heart. TGF-h
stimulation of fibroblasts in turn causes increased expres-
sion of other integrins, e.g. a5h1 and a8h1 [10,18] while
conversely, overexpression of integrins increases TGF-h
expression [11]. Further, TGF-h1 has been shown to
increase MT1-MMP expression in carcinoma cells [105].
It is known that a) MT1-MMP can induce MMP2 and
MMP9 activation, b) that MMP2 and 9 are important
proteases which participate in the remodeling process
[106,107], c) that MMP2 and 9 can activate TNF-a [108],
and d) that TGF-h and TNF-a are also critical modulators of
the remodeling process [36]. Given this, one concept of
remodeling can implicate a complex interplay between MT-
MMPs, integrins, cytokines and the ECM, to modulate
matrix production, cell–matrix adhesion and perhaps cell
migration of fibroblasts.
Another means of ECM remodeling through interactions
between MT-MMPs and integrins might be through
molecules like osteopontin (OPN) (Fig. 4, panel B). OPN
has been classified as a matricellular protein as it resembles
a matrix protein, yet also has cytokine-like properties
including modulation of cellular migration and cell-medi-
ated immunity. It is produced by both cardiac fibroblasts and
myocytes and is upregulated in the hypertrophic and failing
ventricle of humans and animals [109,110]. OPN binds to
several integrins which are expressed on the cardiac
fibroblast. Work in part by our own group has shown that
OPN production is upregulated by AII, that OPN deficient
mice have reduced AII-mediated cardiac fibrosis and
hypertrophy likely due to the decreased adhesion to ECM
and reduced cell proliferation by the OPN/ cardiac
fibroblasts [111]. It is also known that some of the integrins
bound by OPN (e.g. avh3) are expressed on fibroblasts and
can bind MT1-MMP [63]. When in close proximity on the
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 same cell, MT1-MMP may collaborate with avh3 to
increase pro-MMP2 activation and possibly alter cell
migration. This direct interaction is currently unproven in
the myocardium. Additionally, MT1-MMP may process
integrins such as pro-av, a3 and a5. This MT-MMP
mediated processing may be a means to regulate ECM–
matrix adhesion, alter cell migration and perhaps even
integrin signaling in the heart [112]. Again, while this level
of regulation is documented in tumor cells, it remains
hypothetical in the heart.
Binding of h1 integrins to collagen by fibrosarcoma cells
can activate Rac1, which in turn alters both MT1-MMP
transcript expression, its distribution on the cell surface and
then activation of MMP2 [113]. We have studied mice
deficient in h1 integrins specifically in the cardiac myocyte
[114]. These mice develop progressive cardiac fibrosis and
heart failure. Heart tissue from these mice showed
activation of MT1-MMP and MMP2 vs. littermate control
mice at time points which preceded any evidence of
significant fibrosis or decrease in cardiac function (Shai,
S-Y., Spinale, F. and Ross, R.S., unpublished observations).
These results may seem paradoxical when compared to
those in the sarcoma cells above. Thus the specific
interactive role of integrins and MT-MMPs in the myocar-
dium remains poorly understood.
As mentioned, ADAMs are unique in that they possess
dual adhesive and proteolytic domains, and are protein-
solubilizing proteases or ‘‘sheddases’’ [115]. With this
property, the ADAMs can effectively activate pro-molecules
(e.g. ADAM17/TACE mentioned above) or down-modulate
cell surface receptors, in essence causing a ‘‘switching off’’
of signals from a cellular receptor whose ectodomain is
cleaved and ‘‘shed’’ by the ADAM. This mechanism is
appealing in that unlike a progressive down-regulation of
gene expression, here, a threshold signal from one receptor
sub-type (e.g. from a growth factor receptor or perhaps an
integrin) could trigger activation of the ‘‘sheddase.’’ The
sheddase could then cleave the ectodomain of the receptor
that was propagating the initial signal. This would result in
an unambiguous ‘‘off’’ signal as the receptor would no
longer be present. As mentioned, ADAMs can directly
interact with integrins. Goldsmith et al. and Ding et al.
[116,117] have shown that integrins are shed from the
myocyte surface during the evolution of hypertrophy
transitioning to heart failure, but the specific role of
ADAMs in this process is unknown (Fig. 4, panel C). This
process may direct a dynamic modulation of myocyte–
matrix adhesion, perhaps allowing changes in cell shape and
rigidity. Further, shedding of the integrins would defini-
tively alter signals transmitted from outside-in, through the
integrin receptors. These authors have shown integrin
shedding to occur from both cardiac fibroblasts and
myocytes. Fibroblast shedding could allow for a more
proliferative and ‘‘fluid’’ cell which might be required in
both hypertrophic and post-infarct remodeling. The function
of the shed integrin fragment is not well understood butcould potentially provide for feedback inhibition of the
process itself, could block other cell surface intact integrin
receptors from binding to ECM and seems to increase
myocyte (but not fibroblast) adhesion to ECM (specifically
collagen) [116].12. Conclusion
The concepts of cardiac remodeling have evolved greatly
over the last several hundred years. Recent work has begun
to focus on the dynamic role of ECM and cell–ECM
interactions in this process. The membrane associated
molecules discussed in this review all play crucial roles in
allowing cell adhesion to ECM, modification of the ECM
and importantly, significant molecular remodeling of a host
of cell surface and even soluble proteins. While significant
advances have been made in the fundamental biology of
these molecules, their function and particularly their
interaction in the myocardium is poorly understood. We
have provided some hypothetical scenarios regarding the
functional interactions of the integrins, ADAMs and MT-
MMPs. Clearly future studies are required to expand this
knowledge base, and detail the true interactions which occur
on the myocyte, fibroblast and other cells of the heart. This
data could then perhaps allow development of unique
therapeutics which could be used to appropriately modify
the remodeling process.Acknowledgements
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